GM1 Gangliosidosis

Medically reviewed by Jeanine Jarnes, PharmD, MSc, BCPS, BCOP, Associate Professor of Pediatrics, University of Minnesota Medical School, and David Weinstein, M.D., M.M.Sc.
Last updated: July 25, 2026

What is GM1 Gangliosidosis? 

This video explains GM1 gangliosidosis:

The Cause

The genetic lysosomal defect for those with GM1 gangliosidosis results in a deficiency of the enzyme beta-galactosidase. This enzyme is needed to break down and recycle a number of biomolecules. The substance that accumulates most in GM1 gangliosidosis is called GM1 ganglioside. Abundant in neurons, GM1 ganglioside plays important roles in the nervous system, including in cell signaling, neuronal protection, neuronal recovery, and apoptosis. Without beta-galactosidase to break it down, GM1 ganglioside accumulates to toxic levels in cells and eventually causes cell death, predominantly in neurons. When enough neurons die, the nervous system progressively deteriorates, which ultimately leads to death from complications of GM1 gangliosidosis.

References:

1. Regier DS, Tifft CJ, Rothermel CE. GLB1-Related Disorders. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK164500/
2. Rha AK, Maguire AS, Martin DR. GM1 Gangliosidosis: Mechanisms and Management. Appl Clin Genet. 2021. doi:10.2147/TACG.S206076
3. Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008. doi:10.1016/j.ymgme.2008.04.012

Autosomal

In genetics if a gene is autosomal, it means the gene is inherited in the same way by both males and females. In other words, the gene codes for a substance or characteristic that is not unique to male or female genders. The GLB1 gene is autosomal. 

Recessive

Everyone has two copies of each gene, one from their mother and one from their father. Some genes are “dominant,” meaning the trait they code for is expressed regardless of what the other gene in the pair codes for. Some genes are “recessive,” meaning the trait is only expressed if both copies of the gene code for it in the same way.

Inheritance

This refers to something handed down from parents to children, and in genetics, that’s genes and traits. This means a person can only have GM1 gangliosidosis if both of their parents have a copy of the mutated gene and the copy of the mutated gene from each parent was passed down to their child.

This is part of what makes GM1 gangliosidosis so rare. It is unlikely that two carriers have children, and if they do, they only have a 25% chance of having a child with the disease. Ultimately this means that only roughly 1 in 100,000 to 200,000 infants are born with GM1 gangliosidosis each year, and some sources cite figures up to 1 in 300,000. The exact incidence varies depending on the source of the estimate. Newborn screening for GM1 is not yet universal, but advocacy efforts to add GM1 to newborn screening panels are ongoing. Learn more about newborn screening for GM1.

Founder Populations

While GM1 is extremely rare worldwide, it is far more common in certain communities because of founder effects, where a disease-causing mutation is passed down through a historically close-knit population. GM1 has been reported at approximately 1 in 3,700 births in Malta, about 1 in 10,000 among people of Roma ancestry, and roughly 1 in 17,000 in parts of Brazil. Families in these communities may face a higher chance of being carriers, which makes genetic counseling and carrier testing especially valuable.

References:

1. Regier DS, Tifft CJ, Rothermel CE. GLB1-Related Disorders. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK164500/
2. Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008. doi:10.1016/j.ymgme.2008.04.012
3. Centre for Genetics Education. Autosomal Recessive Inheritance.

Symptoms of GM1 Gangliosidosis

Symptoms of GM1 gangliosidosis vary by subtype and by individual, but several features are common across all forms of the disease. Early signs may be subtle and often mimic other conditions, which can delay diagnosis.

Common symptoms across all subtypes include:

• Hypotonia (low muscle tone)
• Ataxia (loss of coordination and balance)
• Dystonia (involuntary muscle contractions)
• Seizures
• Progressive loss of motor and cognitive skills
• Speech and language regression
• Visual impairment

Some children with the infantile form (Type 1) may also show coarsened facial features, enlarged organs (hepatosplenomegaly), and a cherry-red spot on the retina. Symptoms, severity, and rate of progression differ significantly across the four subtypes. Learn more about the subtypes.

How GM1 Gangliosidosis Is Diagnosed

GM1 gangliosidosis is usually confirmed with a combination of biochemical and genetic tests, often after early symptoms prompt evaluation:

• Enzyme testing. A blood test (or a sample of cultured skin cells) measures beta-galactosidase activity. Very low or absent activity is the biochemical hallmark of GM1.
• Genetic testing. Sequencing of the GLB1 gene identifies the two disease-causing variants a child has inherited. This confirms the diagnosis and allows carrier testing for parents and other family members.
• Eye examination. An ophthalmologist may look for a cherry-red spot on the retina, seen in roughly half of children with the infantile form.

Supporting findings can include elevated oligosaccharides in the urine and, in some children, skeletal changes on X-ray (dysostosis multiplex). Newborn screening for GM1 is not yet routine, though advocacy to add it is ongoing. For a deeper walkthrough of testing options, see our GM1 Diagnostic Testing Guide.

History of GM1 Gangliosidosis

Tay-Sachs (GM2 gangliosidosis) was first identified in the late 1800s. It was not until the 1930s that Tay-Sachs was characterized as an “inborn error of metabolism.” Ernst Klenk coined the term “ganglioside” in the early 1940s. It was not until the 1960s, however, that GM1 gangliosidosis was distinguished as its own disease, following Svennerholm’s standardized ganglioside nomenclature (1963) and the enzymatic work of Okada and O’Brien (1968). Read the full history of GM1 gangliosidosis.

GM1 gangliosidosis is also known as Landing disease. Dr. Landing et al first identified the disease in 1964, calling it familial neurovisceral lipidosis.

Other Names and Identifiers

• Landing disease
• Norman-Landing disease
• Gangliosidosis-GM1 beta-galactosidase-1 deficiency

Life Expectancy for Those Living with GM1

GM1 gangliosidosis is highly variable. Although distinct subtypes exist, the disease is a spectrum based on the amount of residual enzyme activity. Families often ask why life expectancy is so difficult to predict. No two cases are exactly the same, and many variables factor in, including day-to-day medical management.

Families make different choices about intervention levels (such as tracheostomy, feeding tube, or clinical trial participation), which affects outcomes. Published life expectancy data also varies by study, since researchers see different patient populations. For example, the Middle East and Malta are known for particularly severe infantile presentations of GM1, while Japan has a higher documented incidence of Type 3 adult-onset GM1. Life expectancy for adult-onset GM1 requires further study, and the diagram below does not reflect it.

Dr. Cynthia Tifft from NIH presented the following diagram in the GM1 Externally-Led Patient-Focused Drug Development meeting with FDA in 2022.

The diagram summarizes how survival differs by subtype and age of onset. In broad terms, the infantile form (Type 1) is the most severe, with life expectancy typically in early childhood; the late-infantile and juvenile forms (Types 2a and 2b) progress more slowly, with survival often into later childhood, adolescence, or early adulthood; and the adult-onset form (Type 3) has the longest and most variable course, with a lifespan that does not appear to be as clearly limited. Because GM1 is a spectrum tied to residual enzyme activity, these are general patterns rather than fixed predictions for any individual.

Source: GM1 Gangliosidosis Externally-Led Patient-Focused Drug Development (PFDD) meeting with the FDA, 2022, presented by Dr. Cynthia Tifft (NIH).

Treatment and Research

As of 2026, there is no approved treatment or cure for GM1 gangliosidosis. Symptom management remains the primary approach and may include anti-seizure medications, muscle relaxants for dystonia, physical therapy, occupational therapy, speech therapy, nutritional support, and palliative care. Research into disease-modifying therapies is actively progressing, and several programs are now in the clinic.

Therapies in Development

• Gene therapy (AAV): The NIH is running a Phase 1/2 study of an intravenous AAV9 gene therapy (AAV9-GLB1) that delivers a working copy of the GLB1 gene, for Type 1 and Type 2 GM1 (NCT03952637). A second gene therapy, PBGM01 from Gemma Biotherapeutics, is delivered into the fluid surrounding the brain for infantile GM1 in a Phase 1/2 study (NCT04713475).
• Small-molecule therapy: Azafaros is running a Phase 3 study of oral nizubaglustat (AZ-3102) in late-infantile and juvenile GM1 and related disorders, the first Phase 3 trial to include GM1 as a primary study population (NCT07054515).
• Enzyme replacement therapy (ERT): ERT involves giving patients the enzyme that isn’t working through infusions into the blood (IV) or into the fluid surrounding the brain. Based on the success of ERT in other lysosomal storage diseases, including the mucopolysaccharidoses, Gaucher, Fabry, and Pompe diseases, Cure GM1 Foundation is directly funding the development of an enzyme replacement therapy to restore the missing beta-galactosidase enzyme. Learn more about our ERT project.

Pharmacological chaperones and other small-molecule approaches are also under investigation. The pipeline has expanded significantly in recent years, and there is real reason for optimism. To see current trials and what participation involves, visit our GM1 Clinical Trials Guide. You can help advance this research by donating.

We invite and encourage anyone interested to take action to further our cause. There are many ways you can use your time and resources to make a difference. Your actions have impact.

To learn more, you can also visit our GM1 gangliosidosis Facts page.

Frequently Asked Questions

What is GM1 Gangliosidosis?

GM1 gangliosidosis is a rare inherited genetic disorder caused by a mutation in the GLB1 gene, which results in a deficiency of the enzyme beta-galactosidase. Without this enzyme, a substance called GM1 ganglioside accumulates in cells, primarily neurons, causing progressive neurodegeneration. It is a progressive, life-limiting disease with no approved cure or treatment; the infantile and juvenile forms are fatal in childhood or adolescence, while the rarer adult-onset form progresses more slowly.

What causes GM1 Gangliosidosis?

Mutations in the GLB1 gene cause GM1 gangliosidosis, leading to a deficiency of the enzyme beta-galactosidase. This is a lysosomal disease, meaning the enzyme deficiency causes harmful substances to build up inside cells. The accumulation of GM1 ganglioside in neurons eventually leads to cell death and the progressive deterioration of the nervous system.

How is GM1 Gangliosidosis inherited?

GM1 gangliosidosis follows an autosomal recessive inheritance pattern. This means a child must inherit one mutated copy of the GLB1 gene from each parent to develop the disease. Parents who each carry one copy of the mutated gene are called carriers and typically show no symptoms themselves. When both parents are carriers, each pregnancy carries a 25% chance of an affected child.

How rare is GM1 Gangliosidosis?

GM1 gangliosidosis is an ultra-rare disease, affecting roughly 1 in 100,000 to 200,000 infants born each year (some sources cite up to 1 in 300,000). An estimated 1 in 250 people in the general population carry a single copy of a disease-causing mutation in the GLB1 gene, though it is far more common in certain founder populations, such as Malta.

What are the subtypes of GM1 Gangliosidosis?

There are four subtypes. Type 1 (Infantile) is the most severe, with onset in the first months of life. Type 2a (Late Infantile) typically has onset around 1 to 3 years, though it can overlap with the infantile range. The juvenile form (Type 2b) has onset between 3 and 10 years. Type 3 (Adult onset) is the mildest form and may not become apparent until adulthood. All subtypes are progressive and currently have no approved treatment.

Is there a treatment or cure for GM1 Gangliosidosis?

As of 2026, there is no approved treatment or cure. Symptom management through medications, physical therapy, and palliative care remains the current standard of care. However, research is advancing. Cure GM1 Foundation is directly funding development of an enzyme replacement therapy (ERT), and additional approaches including gene therapy and small molecule treatments are under active investigation.

---